Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.79 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cycloheptanone SCHEMBL28101629 | 0.96 | TRIM24 (0.85) | TRIM24TRIM33ALDH1A1KMT2ACA1 | |
| Cyclohexanone SCHEMBL2487748 | 0.96 | — | — | |
| Cyclononanone SCHEMBL28385702 | 0.93 | TRIM24 (0.92) | TRIM24TRIM33ALDH1A1KMT2ACA1 | |
| Cyclohexanone SCHEMBL4843445 | 0.93 | — | — | |
| Cycloheptanone SCHEMBL28833619 | 0.93 | — | — | |
| Cycloheptanone SCHEMBL27306619 | 0.89 | TRIM24 (0.85) | TRIM24TRIM33ALDH1A1KMT2ACA1 | |
| Cyclohexanone SCHEMBL27538743 | 0.89 | — | — | |
| Cyclohexanone SCHEMBL3671904 | 0.89 | — | — | |
| SCHEMBL25380098 | 0.89 | TRIM24 (1.00) | TRIM24TRIM33ALDH1A1KMT2ACA1 | |
| Cyclohexanone SCHEMBL713141 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831167-B1 | LIQUID PHASE PROCESS FOR THE SYNTHESIS OF ANNULATED PYRIDINES OVER ZEOLITE TYPE MOLECULAR SIEVE CATALYSTS | COUNCIL SCIENT IND RES (IN) | 2011-07-13 | — | — | EP | disclosed |
| US-7491828-B2 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-02-17 | — | — | US | disclosed |
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | AURKA, CDK4, SKP2 | TRIM24 1413/4885TRIM33 1865/4885ALDH1A1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.